Sign in Subscribe
Communicable diseases

Hepatitis B Virus Reactivation in Stem Cell Transplantation Patients

Strategic Insights

— 1 min read

Researchers in Germany have made a crucial discovery that highlights the risk of hepatitis B virus (HBV) reactivation in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), even if they have resolved HBV infection. The study found that three out of six patients who received stem cell transplants and had pre-transplant antibodies against HBV and hepatitis B core (anti-HBc) antibodies experienced HBV reactivation. The investigators used a highly sensitive HBV-DNA assay to identify the patients at risk, and their findings demonstrate a 50% risk of reverse seroconversion in allo-HSCT recipients with resolved HBV infection.

Key Takeaways:

  • **Risk of HBV reactivation:** The study found a 50% risk of HBV reactivation in allo-HSCT recipients with resolved HBV infection.
  • **Age and HBV status:** The patients who experienced HBV reactivation were those with pre-transplant anti-HBs and anti-HBc antibodies.
  • **HBV-DNA levels:** The study found that the levels of HBV-DNA in serum were elevated before reverse seroconversion in all patients.
  • **Lack of severe liver damage:** Although the patients experienced HBV reactivation, none of them had severe liver damage.
  • **Importance of HBV screening:** The study highlights the importance of screening patients with resolved HBV infection for HBV-DNA before undergoing allo-HSCT.
  • **Treatment implications:** The findings of the study suggest that patients with resolved HBV infection may require antiviral prophylaxis to prevent HBV reactivation after allo-HSCT.
  • **Limitations:** The study had a small sample size, which may limit the generalizability of the findings.

Statistics:

  • 50% risk of HBV reactivation in allo-HSCT recipients with resolved HBV infection (Knoll et al., 2004)
  • 3 out of 6 patients experienced HBV reactivation (Knoll et al., 2004)
  • 12-14 months time period for HBV reactivation to occur after HSCT (Knoll et al., 2004)
  • 10^2-10^3 copies/ml HBV-DNA levels in serum before reverse seroconversion (Knoll et al., 2004)

Sources:

  • Knoll, A., et al. (2004). Reactivation of resolved hepatitis B virus infection after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 33(9), 925-929.
  • NewsRx.com & NewsRx.net (2004, June 28). Stem cell transplants reactivate resolved hepatitis B virus infections. NewsRx.

Read more